Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: implications for future trial design

Pellicori, P. , Vaduganathan, M., Ferreira, J. P., Zannad, F. and Sanyal, A. J. (2022) Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: implications for future trial design. Diabetes and Metabolism, 48(2), 101281. (doi: 10.1016/j.diabet.2021.101281) (PMID:34543735)

Abstract

The natural history of non-alcoholic fatty liver disease (NAFLD) is still not fully elucidated. Patients with NAFLD have a low risk of liver complications, unless substantial liver fibrosis has developed. On the other hand, NAFLD has been linked with excess metabolic and cardiovascular complications. Therapies targeting common pathways may benefit both NAFLD and underlying cardiometabolic risk. Therefore, there is a rationale for considering cardiovascular endpoints in the context of NAFLD trials and, vice-versa, to consider the concomitant presence of NAFLD in drug development for cardiometabolic disorders. This manuscript provides a framework for consideration for future trials examining the inter-relationship between cardiovascular disease and NAFLD.

• Item Type: Articles
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Pellicori, Dr Pierpaolo
• Authors: Pellicori, P., Vaduganathan, M., Ferreira, J. P., Zannad, F., and Sanyal, A. J.
• College/School: College of Medical Veterinary and Life Sciences > School of Health & Wellbeing > Robertson Centre
• Journal Name: Diabetes and Metabolism
• Publisher: Elsevier
• ISSN: 1262-3636
• ISSN (Online): 1878-1780
• Published Online: 17 September 2021
• Copyright Holders: Copyright © 2021 Elsevier Masson SAS
• First Published: First published in Diabetes and Metabolism 48(2): 101281
• Publisher Policy: Reproduced in accordance with the publisher copyright policy